p.froguel@imperial.ac.uk (P.F.), jean-sebastien.annicotte@inserm.fr (J.-S.A.) In Brief Rabhi et al. reveal a role for Kat2b in the control of insulin secretion and pancreatic b cell adaptation to metabolic stress through cell-autonomous regulation of the unfolded protein response (UPR) . These data collected demonstrate that Kat2b expression is decreased in diabetic islets and suggest molecular links among KAT2B, the UPR, and diabetes.
SUMMARY
The endoplasmic reticulum (ER) unfolded protein response (UPR er ) pathway plays an important role in helping pancreatic b cells to adapt their cellular responses to environmental cues and metabolic stress. Although altered UPR er gene expression appears in rodent and human type 2 diabetic (T2D) islets, the underlying molecular mechanisms remain unknown. We show here that germline and b cellspecific disruption of the lysine acetyltransferase 2B (Kat2b) gene in mice leads to impaired insulin secretion and glucose intolerance. Genome-wide analysis of Kat2b-regulated genes and functional assays reveal a critical role for Kat2b in maintaining UPR er gene expression and subsequent b cell function. Importantly, Kat2b expression is decreased in mouse and human diabetic b cells and correlates with UPR er gene expression in normal human islets. In conclusion, Kat2b is a crucial transcriptional regulator for adaptive b cell function during metabolic stress by controlling UPR er and represents a promising target for T2D prevention and treatment.
INTRODUCTION
The endoplasmic reticulum (ER) is a crucial organelle necessary to maintain protein folding and secretory capacity. Defective ER function or prolonged ER stress impairs glucose homeostasis and is associated with the development of peripheral insulin resistance and impaired b cell function, two major contributors to the pathogenesis of diabetes (Walter and Ron, 2011; Wang and Kaufman, 2012) . Several lines of genetic evidence suggest that the transition between an obese, insulin-resistant state to type 2 diabetes (T2D) is triggered by b cell failure, due to both a partial loss of b cell mass and an impaired b cell function (Muoio and Newgard, 2008) . Interestingly, obese patients maintaining b cell compensation are protected from T2D, suggesting that the mechanisms controlling this particular stage of diabetes progression is crucial for the evolution to diabetes (Weir and Bonner-Weir, 2004) .
Pancreatic b cells adapt their secretory capacity to metabolic challenges by activating the ER unfolded protein response (UPR er ), particularly during diet-induced obesity (Eizirik and Cnop, 2010) . The UPR er orchestrates complex signaling pathways in specialized secretory cells undergoing ER stress (Hetz, 2012) . Typically, the UPR er is composed of three transmembrane ER stress sensors, ATF6, IRE1 and PERK, that transduce signaling pathways and, finally, modify the expression of key genes leading to adaptive responses and recovery from ER stress (Back and Kaufman, 2012) . A growing body of evidence suggests that alteration in the expression of UPR er genes may lead to b cell failure and contribute to diabetes development (Cnop et al., 2012; Rabhi et al., 2014) . Recent studies in mouse and human diabetic islets implicate altered expression of these markers (Chan et al., 2013; Engin et al., 2014; Kennedy et al., 2010; Laybutt et al., 2007) . However, the upstream regulators responsible for the modulation of UPR er gene expression are currently unknown. Gene expression relies on the epigenetic status of histones, transcription factors, and their coregulators, allowing cell adaptation to metabolic change (Kelly and Scarpulla, 2004; Mouchiroud et al., 2014) . Adapted responses to different environmental metabolic cues are controlled through the balance between acetylation and deacetylation of specific histone marks and transcription factors (Menzies et al., 2016; Mihaylova and Shaw, 2013; Zhao et al., 2010) . This process involves the antagonistic activity of the chromatin-modifying enzymes lysine/histone deacetylase (KDAC) and lysine/histone acetyl transferase (KAT). Accumulating evidence suggests important roles for KDACs in the control of glucose homeostasis (Mihaylova and Shaw, 2013) , notably by regulating endocrine pancreatic development (Haumaitre et al., 2008; Lenoir et al., 2011) and b cell function and survival (Lundh et al., 2012; Plaisance et al., 2014) . So far, little is known about the metabolic role of KAT, in particular KAT2B. In this study, we investigated the effect of germline and b cellspecific Kat2b deficiency on glucose homeostasis and insulin secretion. We find that loss of Kat2b induces defects in insulin secretion and glucose intolerance. We further establish direct links among Kat2b, UPR er gene expression, and insulin secretion. We also demonstrate that KAT2B expression is defective in T2D islets, providing an unsuspected mechanistic link among KAT2B, UPR er signaling, the ER stress response, and b cell function during metabolic stress.
RESULTS AND DISCUSSION
Germline and b Cell-Specific Kat2b Deficiency Impairs Glucose Tolerance and Insulin Secretion in Mice To elucidate the role of KAT2B in glucose homeostasis, we first investigated the metabolic phenotype of Kat2b-deficient mice (Kat2b À/À) (Maurice et al., 2008; Yamauchi et al., 2000) . Body weight and size of Kat2b À/À mice under a chow diet was reduced when compared to controls (Figures S1A and S1B). The reduced body size was not caused by changes in Igf-1 levels, as liver Igf-1 mRNA levels and serum Igf-1 concentrations were unchanged (Figures S1C and S1D). Kat2b-deficient mice displayed a slight elevation of blood glucose values that was associated with a decrease in plasma insulin levels (Figures 1A and 1B) . Insulin sensitivity was similar between both genotypes ( Figure 1C ), indicating that hyperglycemia in Kat2b À/À mice may result from insulinopenia. Kat2b À/À mice tended to respond to intraperitoneal glucose tolerance tests (ipGTTs; Figures 1D and 1E; p = 0.06) , despite decreased insulin secretion in response to glucose ( Figure 1F ). In contrast to mice fed a regular diet, Kat2b À/À mice fed a high-fat diet (HFD) developed hyperglycemia ( Figure 1G ), insulinopenia ( Figure 1H ), and impaired glucose tolerance ( Figures 1I and 1J ). Impaired glucose homeostasis was correlated with a significant reduction of glucosestimulated insulin levels ( Figure 1K ), despite moderate weight gain ( Figure S1E ; p < 0.01). Insulin sensitivity was similar between Kat2b+/+ and Kat2b À/À mice fed an HFD ( Figure 1L ). We next found that KAT2B protein co-localizes with insulin in healthy rodent islets ( Figures 1M, S1F , and S1G). We then investigated glucose-stimulated insulin secretion (GSIS) in isolated pancreatic islets from Kat2b À/À mice. Although Kat2b deletion did not affect the total insulin content ( Figure S1H ), it reduced GSIS by 56% ( Figure 1N ). Reduction of GSIS was further confirmed in Min6 cells in which Kat2b expression was silenced using interfering RNAs (Figures S1I and S1J). Islet histology (Figure S1K) and cell number and surface area ( Figure 1O ) were similar in chow-fed Kat2b À/À mice. However, islet size of Kat2b À/À mice fed an HFD was significantly reduced when compared to controls ( Figure 1O ; p < 0.001; Figure S1K ). Reduction of islet size was correlated with an increased proportion of small islets ( Figure S1L ). The number of a and b cells per islet and circulating glucagon levels were similar for both diets . With an HFD only, a significant decrease in b cell area was observed in Kat2b À/À pancreata compared to controls ( Figure 1P ; p < 0.001; Figure S1M ), suggesting that Kat2b is required for b cell compensation in obesity and associated insulin resistance.
To further demonstrate the cell-autonomous function of Kat2b on insulin secretion, we generated b cell-specific Kat2b knockout mice by crossing Kat2b
Lox/Lox with RIP-Cre mice (Herrera, 2000) (hereafter referred as Kat2b bÀ/À ; Figure S2A ). Kat2b gene expression analysis on isolated islets demonstrated an efficient recombination upon b cell-specific Cre recombinase expression at the Kat2b locus (Figure 2A ), but not in other metabolic organs including hypothalamus, liver, or adipose tissues ( Figure S2B ). Body weight and fasting glucose levels were similar among all genotypes (Figures 2B and 2C, respectively) . As observed in the germline Kat2b À/À mice, the b cell-specific deletion of Kat2b resulted in glucose intolerance (Figures 2D and 2E) . The Kat2b bÀ/À mice had blunted insulin release 30 min after intraperitoneal glucose administration ( Figure 2F ), whereas their systemic insulin sensitivity was preserved (Figure 2G) . Challenging Kat2b bÀ/À mice with an HFD resulted in moderate body weight gain ( Figure 2H ) and normal fasting glucose levels ( Figure 2I ). However, Kat2b bÀ/À mice fed an HFD were glucose intolerant ( Figures 2J and 2K) , with defective insulin secretion after intraperitoneal glucose administration ( Figure 2L ), but remained sensitive to insulin ( Figure 2M ). Although we cannot rule out off-target effects during our small interfering RNA (siRNA) experiments, these results suggest that Kat2b modulates insulin secretion in a cell-autonomous manner and may contribute to b cell compensation during metabolic stress.
Kat2b Directly Regulates an UPR er Gene Program
Necessary for Proper Insulin Secretion Kat2b directly regulates insulin gene expression in response to glucose through the acetylation of histone H4 (Sampley and Ozcan, 2012) . However, isolated islets from Kat2b +/+ and À/À mice showed no difference in mRNA levels of key genes involved in insulin synthesis (Ins1, Ins2, Pdx1, and Mafa), maturation (Pcsk1, Pcsk2, and Cpe), or secretion (Slc30a8, Kcnj11, Abcc8, and ChgA; Figure S3A ). As Kat2b is a transcriptional coregulator, we performed chromatin immunoprecipitation sequencing (ChIP-seq) in murine isolated islets and showed that DNA motifs present in regions bound by Kat2b were those recognized by several transcription factors, including Pax4, Creb1, Atf4, Atf6, Ddit3 (Chop), and Xbp1 (Table S1 ). Recent evidence demonstrated that altered expression of genes involved in UPR er impairs insulin secretion and b cell function (Back and Kaufman, 2012) . We hypothesized that this pathway may be controlled by Kat2b, and we focused our ChIP-seq analysis on the ER. Gene Ontology (GO) analysis revealed an enrichment of sequences bound by Kat2b involved in different cellular and biological regulations, including the cellular response to a stimulus, the metabolic process, or response to stress (Table S2 ). GO analysis revealed that many genes controlling ER functions (p = 6.4 3 10 À13 ), the ER stress response (p = 0.0027), and UPR er signaling (p = 0.039; Table S2 ) are Kat2b targets. Consistently, Kat2b occupies the promoters of several genes controlling UPR er activity, including Xbp1, Hspa5 (BiP), Atf4, and Atf6 (Table S3 ; Figure S3B ). As ER homeostasis is critical for maintaining b cell function (Fonseca et al., 2011) , we investigated how impaired UPR er regulation in Kat2b À/À islets led to defective insulin secretion. It was previously shown that treatment with chemical chaperones, such as taurine-conjugated ursodeoxycholic acid (TUDCA) and 4-phenyl butyric acid (4-PBA), alleviates ER stress and prevents glucose-induced b cell dysfunction (Tang et al., 2012) . Treatment with both TUDCA and 4-PBA partially rescued GSIS in isolated pancreatic Kat2b À/À islets ( Figure 3A ), suggesting that UPR dysfunction could be responsible for insulin secretion defects.
In Kat2b-silenced Min6 cells, treatment with both molecules also restored GSIS ( Figure S3C ). In accordance with ChIP-seq data, the expression of UPR er genes was decreased in isolated Kat2b À/À islets ( Figure 3B ). This effect was further observed in Kat2b À/À mice fed an HFD ( Figure 3C ), concomitantly with associated decreased expression of key b cell genes such as Mafa, Ins2, and Cpe ( Figure S3D ). Decreased expression of several UPR er genes was confirmed in Kat2b bÀ/À islets (Figure 3D ). Kat2b silencing in Min6 cells further showed UPR er pathway impairment ( Figure S3E ) and decreased expression of b cell genes ( Figure S3F ). Therefore, these findings suggest that Kat2b is an upstream transcriptional regulator of UPR er markers in murine pancreatic islets and Min6 insulinoma cells. Germline or b cell-specific Atf6-deficient (Atf6 bÀ/À ) mice have decreased insulin secretion (Engin et al., 2014; Usui et al., 2012) . The striking similarity between the Kat2b À/À mice and Atf6-deficient mice prompted us to focus on the regulation of the Atf6 gene by Kat2b. In agreement with our ChIP-seq and qPCR data, luciferase-based reporter studies confirmed that Kat2b potentiates the promoter activity of the Atf6 gene construct in Min6 cells ( Figure 4A ). This transcriptional effect relied on Kat2b acetyltransferase activity. A Kat2b construct deleted of its HAT domain was unable to stimulate the luciferase gene ( Figure 4A ). Importantly, rescue of Atf6 expression in Kat2b À/À islets ( Figures 4B and S4A ) and in Kat2b-silenced Min6 cells ( Figures 4C and S4B ) restored glucose-stimulated insulin secretion in these cells, demonstrating that Atf6 mediated the observed effects of Kat2b on insulin secretion. To further evaluate the contribution of Kat2b to the ER stress response, we treated Min6 cells with the ER stress inducer thapsigargin (TG). This treatment did not modulate Kat2b mRNA levels ( Figure 4D ), but it rapidly increased Kat2b protein levels ( Figures 4E and 4F ). The rise of Kat2b abundance by TG was confirmed at lower doses ( Figure S4C ) and in cells exposed to the lipotoxic agent palmitate ( Figure S4D ). Interestingly, we identified a potential upstream open reading frame (uORF) within the Kat2b gene that may contribute to this (D-F) ipGTT measuring the levels of glucose (D), the corresponding AUC (E) and insulin (F) at the indicated times after intraperitoneal injection of glucose in 5-month-old Rip-Cre/+ (black triangles and bars, n = 11), Kat2b b+/+ (white circles and bars, n = 11), and Kat2b bÀ/À (green squares and bars, n = 11).
(G) ipITT measuring levels of glucose at the indicated times after intraperitoneal injection of insulin in mice fed normal chow (n = 11).
(H) Body weight gain under HFD feeding of Rip-Cre/+ (n = 8), Kat2b b+/+ (n = 6), and Kat2b bÀ/À (n = 10).
(I) 16 hr fasting blood glucose levels in Rip-Cre/+ (n = 4), Kat2b b+/+ (n = 10), and Kat2b bÀ/À (n = 11) mice fed an HFD for 16 weeks.
(J-L) ipGTT measuring the levels of glucose (J), the corresponding AUC (K), and serum insulin (L) at the indicated times after intraperitoneal injection of glucose in Rip-Cre/+ (black triangles and bars, n = 11), Kat2b b+/+ (white circles and bars, n = 11), and Kat2b bÀ/À (green squares and bars, n = 11) mice fed an HFD for 16 weeks.
(M) ipITT measuring the levels of glucose at the indicated times after intraperitoneal injection of insulin in mice fed an HFD (n = 6-11). All values are expressed as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001.
regulation (data not shown). In contrast to Kat2b, TG increased Atf6 mRNA levels ( Figure 4G ). This induction was lowered upon Kat2b silencing, suggesting that Kat2b may contribute to Atf6 regulation under stress conditions ( Figure 4G ). ChIP-qPCR in Min6 cells confirmed Kat2b binding on the Atf6 promoter (Figure 4H ). The regulation of the Atf6 promoter by Kat2b was independent of histone H3 acetylation, since no modulation of the H3ac, H3K9ac, or H3K14ac epigenetic marks was observed upon Kat2b silencing in Min6 cells ( Figure S4E ). The Pdx1 promoter was, however, modulated by Kat2b-dependent acetylation of histone H3 ( Figure S4E ). This suggests that the regulation of Atf6 promoter activity may operate through the acetylation of non-histone proteins. Moreover, recruitment of Kat2b on the Atf6 promoter was increased in the presence of TG (Figure 4H) . To further study the contribution of Kat2b in UPR er signaling, activation of several key UPR er proteins was monitored upon reduction of Kat2b levels. Silencing of Kat2b decreased the amount of total PERK, phosphorylated PERK, Hspa5, phosphorylated IRE1a, and its target, spliced Xbp1 and Atf6, in response to TG treatment ( Figure 4I ). Altogether, these data suggest that Kat2b is a permissive transcriptional co-activator controlling several branches of the UPR er pathway under both basal and stress conditions. Our results also emphasize that Kat2b mostly affects the Atf6 branch of the UPR er . The regulation of the Kat2b uORF by the PERK-eIF2a
arm of the UPR is currently unknown but might represent a mechanistic link between ER-stress-dependent UPR er activation and the regulation of UPR er target genes targeted by Kat2b.
Decreased Kat2b Expression in Rodent and Human T2D Islets
We then quantified Kat2b expression in rodents and human diabetic islets. Kat2b expression was significantly reduced in 20-week-old db/db pancreatic islets compared to non-diabetic db/+ mice ( Figures 5A and 5B ). Immunofluorescence assays on formalin-fixed human pancreatic sections showed that insulinproducing b cells and non-b cells expressed KAT2B ( Figure 5C ). Islet transcriptomics analysis in T2D subjects from two independent datasets demonstrated a significant decrease of KAT2B mRNA levels compared to normal glycemic controls (GEO: GSE20966; Marselli et al., 2010; and GEO: GSE38642; Taneera et al., 2012; Figures 5D and 5E, respectively) . Moreover, KAT2B expression in human islets was inversely correlated with the long-term glucose control marker glycated hemoglobin A1c (HbA1c; Figure 5F ). By analyzing fresh human islets isolated from four T2D donors and four normoglycemic subjects (see Table S4 for donor information), we confirmed that KAT2B expression was decreased in T2D ( Figure 5G ). Some UPR er pathways are defective in human T2D islets; Engin et al., 2014; Kennedy et al., 2010) . In this respect, KAT2B expression, ABCC8, SLC30A8, CPE, PDX1, and UPR er genes DDIT3 (CHOP), HERPUD2, HSP90B1 (GRP94), EDEM1, and DNAJC3 (p58IPK) were concomitantly decreased in T2D islets ( Figure 5H ). In human islets, KAT2B and the expression of genes controlling UPR er and b cell function were positively correlated ( Figure 5I) . Moreover, KAT2B, UPR er and b cell function genes are part of the same gene cluster ( Figure 5J ). Silencing of KAT2B expression in healthy human islets , and Kat2b bÀ/À mice fed chow (n = 3).
Data are shown as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001.
decreased GSIS ( Figures 5K and 5L ) with a concomitant decrease in ATF6 and XBP1 mRNA levels ( Figure 5M ). Interestingly, analysis of ChIP-seq data from ENCODE (http://genome. ucsc.edu/ENCODE/) showed that KAT2B binds to numerous UPR er genes in human cell lines, including ATF6, XBP1, ATF4, HSPA5, DDIT3, and HERPUD2 ( Figures S5-S7 ). These results are reminiscent of our ChIP-seq analysis in murine pancreatic islets. Formaldehyde-assisted isolation of regulatory elements (FAIRE)-sequencing (Giresi et al., 2007) and DNasesequencing (Crawford et al., 2006) data further revealed that these UPR er chromatin regions were associated with regulatory activities in pancreatic human islets (Figures S5-S7) . In combination, these results strongly support the existence of a link between KAT2B and UPR er gene expression in human islets and correlate defective KAT2B expression with T2D status in human pancreatic islets.
Our results suggest that KAT2B is likely to be an important mediator of insulin secretion and b cell adaptation during metabolic stress. Indeed, both germline and b cell-specific deletion of Kat2b in the mouse induces glucose intolerance and defective insulin secretion. Although we cannot rule out that Kat2b modulates other pathways involved in b cell function, our data from rodent models suggest that Kat2b directly regulates UPR er gene expression. We found in human islets a robust association between the expression of this lysine acetyltransferase and crucial genes involved in insulin secretion and in b cell adaptive responses. By regulating UPR er signaling pathways, KAT2B can be considered a critical transcriptional regulator of b cell function, especially after metabolic stress (Figure 6 ). The decrease of KAT2B expression in T2D islets and the inverse correlation with HbA1C levels further suggest a potential role for KAT2B during the onset of T2D.
During obesity, b cells need to adapt their insulin secretory capacity in response to nutrient overload by progressively expanding their islet cell mass (Weir and Bonner-Weir, 2004 ). Under diabetogenic conditions, Kat2b À/À mice are unable to compensate (Figure 1) . ob/ob mice and hyperglycemic db/db mice display differential regulation of the adaptive UPR er (Chan et al., 2013) . The expression of UPR er genes is induced in islets Data are shown as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001.
of non-diabetic ob/ob mice, whereas it progressively decreases in diabetic db/db mice, linking UPR er failure with progression to diabetes (Chan et al., 2013) . Our observations that Kat2b levels are decreased in b cells of db/db mice suggest a molecular mechanism linking defective glucose homeostasis and UPR er in these mice.
In conclusion, our study suggests that Kat2b contributes to the maintenance of efficient UPR er levels in b cells to ensure an efficient adaptive response to stressful conditions, such as those inflicted by obesity and metabolic stress. Therefore, it is our expectation that the evidence presented here will guide the rationale and design of future therapeutic strategies by incorporating KAT2B-targeted drugs against T2D and related disorders such as obesity.
EXPERIMENTAL PROCEDURES

Materials and Oligonucleotides
Chemicals, unless stated otherwise, were purchased from Sigma-Aldrich. Anti-INS (ab7842), anti-ATF6 (ab11909), anti-KAT2B (ab96510 for immunofluorescence, ab12188 for ChIP), and Igg (ab37415 ChIP grade) antibodies were from Abcam; anti-KAT2B (sc-13124 for western blot), anti-actin (sc-1616), and anti-Xbp-1 antibodies were from Santa Cruz Biotechnology; anti-glucagon was from Sigma-Aldrich; and anti-PERK (C33E10), phospho-PERK (16F8), phospho-IRE1a (14C10), and anti-Hspa5 (C50B12) were from Cell Signaling. The oligonucleotides sequences used for various experiments are listed in Table S5 . Plasmids with Kat2b cDNA were kindly provided by Drs. L.K. Linares and C. Gongora, and ATF6-pGL3 construct was kindly provided by Pr. Yoshida. The adenovirus encoding human ATF-6 has been described elsewhere (Sharma et al., 2015) .
Animal Experiments
Mice were maintained according to European Union guidelines for the use of laboratory animals. In vivo experiments were performed in compliance with the French ethical guidelines for studies on experimental animals (animal house agreement no. A 59-35015, Authorization for Animal Experimentation no.59-350294, project approval by our local ethical comitttee no. CEEA 482012). Germline Kat2b-deficient mice were previously described (Duclot et al., 2010) , and experiments were performed on CD1 strains. All experiments were performed with male mice. Mice were housed under a 12-hr light/dark cycle and given a regular chow (A04;Safe). For HFD studies, 5-week-old mice were placed on a D12492 diet (60% of calories from fat; Research Diet) for 13 weeks. Metabolic phenotyping experiments were performed according to the EMPRESS protocols. Intraperitoneal glucose and insulin tolerance tests (ITTs) were performed as previously described (Annicotte et al., 2009 ) on 16-hr-fasted animals for ipGTT and 5-hr-fasted animals for ITT. Glycemia was measured using the Accu-Check Performa (Roche Diagnostics). Circulating insulin levels were measured using the Ultrasensitive Insulin ELISA kit (Mercodia). Circulating Igf-1 levels were measured on fed animals using an Igf-1 ELISA kit (Sigma-Aldrich). Kat2b floxed (Kat2b L2/L2 ) mice were generated by homologous recombination in 129Sv embryonic stem (ES) cells according to standard pro- (Argmann et al., 2005) . The karyotype was verified and several correctly targeted ES cell clones were injected into blastocysts from C57BL/6J mice. These blastocysts were transferred into pseudopregnant females, resulting in chimeric offspring that were mated to female C57BL/6J mice that express Flp recombinase under the control of the ubiquitous cytomegalovirus promoter (Rodríguez et al., 2000) .
Offspring that transmitted the mutated allele, in which the selection marker was excised, and that lost the Flp transgene (Kat2b L2/WT mice) were selected and backcrossed for over ten generations with C57BL/6J mice. The congenic mice carrying the floxed Kat2b allele were thereafter mated with rat insulin II promoter (RIP)-Cre mice (Herrera, 2000) mice.
Immunofluorescence, Immunohistochemistry, and Morphometry
Immunofluorescence and immunohistochemistry were performed exactly as described previously (Annicotte et al., 2009; Blanchet et al., 2011) . Pancreatic tissues were fixed in 10% formalin, embedded in paraffin, and sectioned at 5 mm. H&E staining was performed using classical protocols. For immunofluorescence microscopy analyses, after antigen retrieval using citrate buffer, 5-mm formalin-fixed pancreatic sections were incubated with the indicated antibodies. Immunofluorescence staining was revealed by using a fluorescein-isothiocyanate-conjugated anti-rabbit (for Kat2b; Life Technologies) or anti-guinea pig (for insulin co-staining with glucagon), Alexa-conjugated anti-mouse (for glucagon) or anti-guinea pig (for insulin co-staining with Kat2b) secondary antibodies. Nuclei were stained with Hoechst. For morphometric analysis, three to ten animals from each genotype were analyzed, and images were processed and quantified using ImageJ software by an observer blinded to experimental groups. Human pancreatic sections were obtained from Biochain.
Pancreatic Islet Studies
Human pancreatic tissue was harvested from brain-dead, non-diabetic, and T2D adult human donors (Table S4 ). Isolation and islet culture were performed as described elsewhere (Kerr-Conte et al., 2010) . For mouse islet studies, pancreata were digested by type V collagenase (C9263; 1.5 mg/ml) for 20 min at 37 C as described previously (Annicotte et al., 2009) . Briefly, after digestion and separation in a density gradient medium, islets were purified by handpicking under a macroscope. For insulin secretion tests, approximately ten islets were exposed to either 2.8 mM or 20 mM glucose in Krebs-Ringer bicarbonate HEPES buffer containing 0.5% fatty-acid-free BSA. Insulin released in the medium was measured 1 hr later using the Ultrasensitive Insulin ELISA kit. Data are expressed as a ratio of total insulin content. For mRNA and protein quantification, islets were isolated as described above and snap-frozen for further processing. For ATF-6 rescue experiments, isolated islets were transfected as described previously (Annicotte et al., 2009 ).
Cell Culture, Transfections, Adenoviral Transduction, and Treatments Min6 cells were cultured in DMEM (Gibco) with 15% fetal bovine serum, 100 mg/ml penicillin-streptomycin, and 55 mM beta-mercaptoethanol. Cell were transfected with siRNA targeting mouse Kat2b ON-TARGETplus SMARTpool (Thermo Scientific) and mouse non-targeting negative controls using Dharmafect1 (GE Dharmacon). Mouse islets and Min6 cells were treated as described previously (Wali et al., 2014) with TUDCA (0.5 mM) and 4-PBA (2.5 mM) for 48 hr and subjected to GSIS. Min6 cells were treated with TG (0.5-2.5 mM; Sigma) to induce ER stress and then with BSA-conjugated palmitate (1.5 mM) for 24 hr. Transient transfection were performed using Lipofectamine 2000 (Life Technologies) following the manufacturer's instructions. Luciferase assays were performed 48 hr post-transfection and normalized to b-galactosidase activity. For rescue experiments using adenoviral infection, Min6 cells were transduced at a MOI of 50 for 4 hr; cells were then washed and cultured for 48 hr before GSIS tests. Experimental data as presented are means of at least three independent experimental experiments.
ChIP and ChIP Sequencing
ChIP-qPCR assays were performed as described previously (Annicotte et al., 2009) . Briefly, proteins from Min6 cells were formaldehyde crosslinked to DNA. After homogeneization, lysis, and DNA sonication, proteins were immunoprecipitated using purified immunoglobulin G or anti-KAT2B antibodies. After washing, DNA-protein complexes were eluted and crosslinking was reversed by heating the samples at 65 C for 16 hr. DNA was then purified using a Macherey-Nagel NucleoSpin Gel and PCR purification kit, and ChIP-qPCR was performed using promoter-specific primers. All ChIPs and qPCRs were repeated three times. ChIP assays were performed in triplicate on $600 mouse isolated islets using the True MicroChIP kit (Diagenode) following the manufacturer's protocol. ChIP-seq libraries were prepared using NEBNext-Ultra kits (New England Biolabs) following the manufacturer's instructions. DNA libraries were quantified by Qubit (Invitrogen) and sequenced using a Hiseq 2500 instrument in single-end 50-bp reads (Illumina).
ChIP-Seq Data Analysis
ChIP-seq was performed in triplicate. Short DNA reads were aligned against the mouse mm9 reference genome using Bowtie 2 (Langmead and Salzberg, 2012) . Only unique aligned reads were analyzed. The mapped replicates were merged and chromatin binding sites were identified using model-based analysis of ChIP-seq (MACS) (Zhang et al., 2008) . Input DNA was used as a control, and parameters recommended for analysis of ChIP-seq data were applied (Feng et al., 2011) . ChIP-seq experiments were visualized with the UCSC Genome browser as described elsewhere (Robertson et al., 2007) . Peak summits were annotated to gene products by identifying the nearest RefSeq transcription start site using Peak2gene. Raw and processed ChIP-seq data have been deposited to Gene Expression Omnibus (GEO: GSE78860).
Public functional genomics data used in this study were downloaded from the GEO and are listed in Table S6 . Human ChIP-seq data were obtained from ENCODE and visualized using the UCSC Genome browser as described above.
RNA Extraction, Measurements, and Profiling Total RNA was extracted from cells and tissues using TRIzol reagent (Life Technologies) as described previously (Annicotte et al., 2009; Blanchet et al., 2012) . mRNA expression was measured after reverse transcription by real-time qPCR with FastStart SYBR Green master mix (Roche) according to the manufacturer's recommendations and gene-specific oligonucleotides. Mouse real-time qPCR results were normalized to endogenous cyclophilin reference mRNA levels, and human results were normalized to TATA-box binding protein (TBP). Results are expressed as the relative mRNA level of a specific gene expression using the formula 2 ÀDCt .
Protein Extracts and Immunoblot Analysis
Immunoblot was performed as described previously (Blanchet et al., 2012) . Briefly, cells were washed using cold PBS and lysis was performed by using 50 mM Tris-HCl (pH 8), 137 mM NaCl, 10% glycerol, 1% NP-40 and phosphatase, protease, and deacetylase inhibitors (Sigma-Aldrich) on ice. Western blotting was performed using 30 mg of proteins loaded on SDS-PAGE precast gel (Bio-Rad). After electrotransfer, the membrane was blocked for 1 hr at room temperature with 5% nonfat milk in 0.1% Tween Tris-buffered saline (TTBS) buffer. Membranes were then incubated overnight at 4 C with primary antibodies as indicated in blocking buffer containing 5% nonfat milk at the dilution specified by the manufacturers. Membranes were then incubated with the secondary antibody conjugated with the enzyme horseradish peroxidase. The visualization of immunoreactive bands was performed using the enhanced chemiluminescence plus western blotting detection system (GE Healthcare). Quantification of protein signal intensity was performed by volume densitometry using ImageJ 1.47t software (NIH).
Human Islet Expression Data and Correlation Studies
To identify transcriptomic datasets from human pancreatic islets, GEO analysis from the NCBI was performed using ''human islet T2D'' as keywords and filtered with ''Datasets.'' Three datasets were obtained, and two were selected based on the highest number of samples (GEO: GSE38642; Taneera et al., 2012; and GEO: GSE20966; Marselli et al., 2010) . Datasets were downloaded from the GEO and analyzed with Gene Set Enrichment Analysis (GSEA; http://software.broadinstitute.org/gsea/) as described previously (Ryu et al., 2014) . Correlation studies were based on Pearson's correlation coefficient and represented using R.
Statistical Analysis
Data are presented as mean ± SEM. Statistical analyses were performed using an unpaired two-tailed Student's t test, one-way ANOVA with a least significant difference Bonferroni post hoc test or two-way ANOVA with Bonferroni post hoc tests, as appropriate, using GraphPad Prism software. Differences were considered statistically significant at p < 0.05 (*p < 0.05, ** p < 0.01, and *** p < 0.001).
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